Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Terminated 4Completed 2Unknown 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Thyroid Diseases 1Prostatic Neoplasms 1Neoplasms 1Melanoma 1Lymphoma 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × tomivosertib × Clear all
NCT03690141 2024-06-21

An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer

Effector Therapeutics

Phase 2 Terminated
16 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT02605083 2020-11-02

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

Effector Therapeutics

Phase 1/2 Terminated
66 enrolled
DermatologicHead & Neck

Melanoma, Neoplasms, Thyroid Diseases

NCT02937675 2020-11-02

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Effector Therapeutics

Phase 1/2 Terminated
28 enrolled
Lymphoid

Lymphoma

NCT03318562 2019-07-18

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Effector Therapeutics

Phase 2 Terminated
3 enrolled
BreastGastrointestinal

Carcinoma, Hepatocellular, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡